Hearth Failure With Reduced Ejection Fraction (HFrEF) Clinical Trial
Official title:
Prospective, Multi-center, Open lAbel, Post-appRovAl Study AImed at Characterizing the Use of LCZ696 at 97 mg Sacubitril / 103 mg Valsartan Bid in Patients With HFrEF
The primary purpose of the study was to describe the tolerability of treatment with the
optimal dose of LCZ696 (97 mg sacubitril / 103 mg valsartan bid), over six (6) months, in
patients with heart failure with reduced ejection fraction (HFrEF) in Canada.
The study was also to describe the overall tolerability, effectiveness and safety of LCZ696
for the management of HFrEF over 12 months of treatment, as well as describe the patterns of
LCZ696 up and down dose titrations occurring during the management of patients with HFrEF.
n/a